Shrna vector

The shRNA vectors were purchased from GeneChem Company (Shanghai,China). The S100A12#1 sequence was 5′-CGACTTTCAAGAATTCATA-3′,the S100A12#2 sequence was 5′- GGATGCTAATCAAGATGAA − 3′ and the shRNA control (shNC) sequence was 5′- TTCTCCGAACGTGTCACGT − 3′.

The human acute monocytic leukemia cell line THP-1 (ATCC: TIB-202^TM) and human LUAD cell lines HCC827 (ATCC: CRL-2868^TM) and A549 (ATCC: CCL-185^TM) were acquired from American Type Culture Collection (ATCC). THP-1 and HCC827 were cultured in RPMI 1640 (Gibco, Carlsbad, CA, USA), and A549 was cultured in DMEM/F12 (Gibco, Carlsbad, CA, USA). All cell lines were cultured in a medium supplemented with 10% fetal bovine serum (FBS, Gibco, Carlsbad, CA, USA) and 1% penicillin/streptomycin solution, and maintained at 37 °C with 5% CO₂. These three cell lines were confirmed to be mycoplasma free and were passaged < 10 times after the initial recovery of the frozen stocks. All cell lines were authenticated by performing short tandem repeat profiling before use.
Human TIAM2 complement DNA (cDNA) expression vector was constructed by Public Protein/Plasmid Library (Nanjing, China) with pLVX-EF1alpha-IRES-Puro (catalog no. 631988; Clontech, Mountain View, CA, USA).
The shRNA vectors specifically targeting TIAM2 (shTIAM2#1: 5′-GTTAAGGTGATTCGTTCTATT-3′; shTIAM2#2: 5′-GCCCTACTAAAGACATCGAAA-3′) and a scramble control vector (shGFP: 5′-GCAAGCTGACCCTGAAGTTCA-3′) were purchased from Genechem (Shanghai, China). All the plasmid vectors were verified by performing sequencing [84 (link)].